Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
taletrectinib (AB-106)
i
Other names:
AB-106, DS6051b, DS-6051a, DS-6051, DS 6051, DS6051, DS-6051b, AB106, IBI-344
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(5)
News
Trials
Company:
Baoyuan Biopharma, Daiichi Sankyo, Innovent Biologics, NewG Lab Pharma, Nippon Kayaku
Drug class:
TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor antagonist
Related drugs:
‹
larotrectinib (189)
entrectinib (178)
PBI-200 (0)
lorlatinib (94)
repotrectinib (27)
iruplinalkib (11)
SAF-189 (7)
TQ-B3101 (6)
SIM1803-1A (5)
APG-2449 (4)
TGRX-326 (3)
TQ-B3139 (3)
AGX87 (0)
TY-2136b (0)
XZP-3621 (0)
XZP-5955 (0)
ZG0418 (0)
NVL-520 (0)
K-252a (1)
VMD-928 (0)
larotrectinib (189)
entrectinib (178)
PBI-200 (0)
lorlatinib (94)
repotrectinib (27)
iruplinalkib (11)
SAF-189 (7)
TQ-B3101 (6)
SIM1803-1A (5)
APG-2449 (4)
TGRX-326 (3)
TQ-B3139 (3)
AGX87 (0)
TY-2136b (0)
XZP-3621 (0)
XZP-5955 (0)
ZG0418 (0)
NVL-520 (0)
K-252a (1)
VMD-928 (0)
›
Associations
(5)
News
Trials
VERI cancer hierarchy
Reset Filters
ROS1 fusion
Non Small Cell Lung Cancer
ROS1 fusion
Non Small Cell Lung Cancer
AB-106
Sensitive: B - Late Trials
AB-106
Sensitive
:
B
AB-106
Sensitive: B - Late Trials
AB-106
Sensitive
:
B
CD74-ROS1 fusion
Non Small Cell Lung Cancer
CD74-ROS1 fusion
Non Small Cell Lung Cancer
AB-106
Sensitive: C2 – Inclusion Criteria
AB-106
Sensitive
:
C2
AB-106
Sensitive: C2 – Inclusion Criteria
AB-106
Sensitive
:
C2
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
AB-106
Sensitive: C2 – Inclusion Criteria
AB-106
Sensitive
:
C2
AB-106
Sensitive: C2 – Inclusion Criteria
AB-106
Sensitive
:
C2
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
AB-106
Sensitive: C3 – Early Trials
AB-106
Sensitive
:
C3
AB-106
Sensitive: C3 – Early Trials
AB-106
Sensitive
:
C3
TPM3-NTRK1 fusion
Thyroid Gland Papillary Carcinoma
TPM3-NTRK1 fusion
Thyroid Gland Papillary Carcinoma
AB-106
Sensitive: C4 – Case Studies
AB-106
Sensitive
:
C4
AB-106
Sensitive: C4 – Case Studies
AB-106
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login